De Zorzi, Elena
Spagnolo, Paolo
Cocconcelli, Elisabetta
Balestro, Elisabetta
Iaccarino, Luca
Gatto, Mariele
Benvenuti, Francesco
Bernardinello, Nicol
Doria, Andrea
Maher, Toby M.
Zanatta, Elisabetta
Article History
Accepted: 11 January 2022
First Online: 18 March 2022
Change Date: 21 July 2022
Change Type: Update
Change Details: The original version of this paper was updated to present the missing Open Access funding note.
Declarations
:
: PS reports institutional grants, personal fees and non-financial support from PPM Services and Boehringer Ingelheim, institutional grants from Roche and personal fees from Galapagos, Chiesi, Novartis, Lupin, Pieris and Santhera Pharmaceuticals, outside of the submitted work. EZ received honoraria for lectures and educational events from Boehringer-Ingelheim, Actelion and GSK. LI received honoraria for lectures and educational events from GSK. TM reports consulting fees from Boehringer Ingelheim, Roche/Genentech, Astra Zeneca, Bayer, Blade Therapeutics, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline, IQVIA, Pliant, Respivant, Theravance and Veracyte, and honoraria for lectures or educational events from Boehringer Ingelheim and Roche/Genentech. NB received a technical consultancy contract from Chiesi. EB reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. AD received honoraria/speaking fees from GSK, Eli-Lilly, Roche, Janssen, Pfizer. All other authors declared no relevant financial or non-financial interests.